©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Cellular Stresses Differentially Activate c-Jun N-terminal Protein Kinases and Extracellular Signal-regulated Protein Kinases in Cultured Ventricular Myocytes (*)

(Received for publication, July 12, 1995; and in revised form, October 4, 1995)

Marie A. Bogoyevitch (§) Albert J. Ketterman Peter H. Sugden

From the From Cardiac Medicine, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London SW3 6LY, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Anisomycin or osmotic stress induced by sorbitol activated c-Jun N-terminal protein kinases (JNKs) in ventricular myocytes cultured from neonatal rat hearts. After 15-30 min, JNK was activated by 10-20-fold. Activation by anisomycin was transient, but that by sorbitol was sustained for at least 4 h. In-gel JNK assays confirmed activation of two renaturable JNKs of 46 and 55 kDa (JNK-46 and JNK-55, respectively). An antibody against human JNK1 immunoprecipitated JNK-46 activity. Endothelin-1, an activator of extracellular signal-regulated protein kinases (ERKs), also transiently activated JNKs by 2-5-fold after 30 min. Phorbol 12-myristate 13-acetate did not activate the JNKs although it activated ERK1 and ERK2, which phosphorylated the c-Jun transactivation domain in vitro. ATP depletion and repletion achieved by incubation in cyanide + deoxyglucose and its subsequent removal from the medium activated the ERKs but failed to activate the JNKs. Sorbitol (but not anisomycin) also stimulated the ERKs. Sorbitol-stimulated JNK activity could be resolved into three peaks by fast protein liquid chromatography on a Mono Q column. The two major peaks contained JNK-46 or JNK-55. These results demonstrate that cellular stresses differentially activate the JNKs and ERKs and that there may be ``cross-talk'' between these MAPK pathways.


INTRODUCTION

The mammalian ventricular myocyte is a terminally differentiated cell that responds to neurohumoral or mechanical stimuli by adaptational growth in the absence of cell division (hypertrophy)(1) . Increases in cell size and myofibrillar content are accompanied by transcriptional changes such as the rapid but transient expression of the immediate-early genes c-fos, c-jun, and egr-1 that encode transcription factors(1) . Expression of c-fos has been used as an early marker of the hypertrophic response in the heart (2) and is controlled by multiple promoter elements that include the serum response element, the sis-inducible element, the activator protein-1 element (AP-1), (^1)and the cAMP response element(3) . Regulation via the serum response element involves the phosphorylation of the ternary complex factor p62 (or Elk-1) by the extracellular signal-regulated protein kinase (ERK) subfamily of mitogen-activated protein kinases (MAPKs)(^2)(4) , whereas the sis-inducible element is involved in receptor protein tyrosine kinase signaling(3) . Once expressed, Fos and other members of the Fos-related family of transcription factors heterodimerize with members of the c-Jun family and transactivate at promoter regions containing AP-1 sites(5) .

Rapid changes in transcriptional activity also follow the phosphorylation of c-Jun on Ser-63 and Ser-73 in its N-terminal transactivation domain(6, 7) . Although ERKs will phosphorylate Ser-63 and Ser-73, another protein kinase, pp54, also phosphorylates these residues(7) . This Ser/Thr protein kinase has been identified as a member of a c-Jun N-terminal kinase (JNK) subfamily of MAPKs(8) . JNKs are only weakly activated by growth factors or phorbol esters, but are strongly activated by inflammatory cytokines and cellular stresses such as UV radiation, heat shock or protein synthesis inhibition (9, 10, 11) .

We recently proposed an involvement of the Ras Raf MEK ERK pathway in the development of hypertrophy of the ventricular myocyte (12, 13) . This has been supported by studies in which transfection of ventricular myocytes with [Val]Ha-Ras(14) , active forms of c-Raf (15) or constitutively activated forms of MEK (16) produced changes in gene expression that were qualitatively similar to those observed after treatment with hypertrophic agonists (1) . Transfection of myocytes with a dominant-negative form of ERK1 prevented these changes in gene expression induced by the hypertrophic agonist phenylephrine(17) .

The ventricular myocyte must also adapt hypertrophically to cellular stress, such as myocardial ischemia, or reperfusion of an ischemic region(18, 19) . Although myocytes in the affected region may be irreversibly damaged and subsequently die, myocytes bordering on the damaged zone increase in size to maintain the overall contractile capacity of the heart(18, 20) . Given that the transcriptional activation observed during the hypertrophic response could involve activation of growth-related protein kinases additional to ERKs, we have examined the activation of isoforms of JNKs and ERKs in cultured neonatal rat ventricular myocytes exposed to cellular stresses or hypertrophic neurohumoral stimuli.


EXPERIMENTAL PROCEDURES

Materials

Sorbitol, anisomycin, phorbol 12-myristate 13-acetate (PMA), endothelin-1 (ET-1), phenylephrine, ionomycin, 2-deoxy-D-glucose (DOG), Medium 199 (M199), Dulbecco's modified Eagle's medium (DMEM), protease inhibitors, and bovine myelin basic protein (MBP) were from Sigma. Other tissue culture products were from Life Technologies, Ltd. Prestained molecular mass standard proteins, horseradish peroxidase-linked donkey anti-rabbit immunoglobulin, the enhanced chemiluminescence (ECL) Western blotting detection reagents, and autoradiography film (Hyperfilm MP) were from Amersham International. [-P]ATP was from DuPont NEN. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) reagents and reagents to assay protein by the method of Bradford (21) were from Bio-Rad. An agarose-conjugated affinity-purified rabbit polyclonal antibody raised against the 17 amino acid peptide derived from the C terminus (KNGVIRGQPSPLAQVQQ) of JNK1 (22) and the immunizing peptide were from Santa Cruz Biotechnology Inc. Antiserum raised against the C-terminal peptide sequence KEKLKELIFEETAR from mouse ERK2 (23) was a gift from C.J. Marshall, Chester Beatty Laboratories, Institute of Cancer Research, London, UK. Recombinant c-Jun containing the N-terminal regulatory region of amino acids 1-135 (c-Jun(1-135)) was expressed as a glutathione S-transferase (GST) fusion protein in Escherichia coli(24, 25) (clone provided by C. J. Marshall) and was purified by glutathione-Sepharose (Pharmacia) chromatography. It was stored at -80 °C in buffer containing 5% glycerol (protein concentration 50 mg/ml).

Primary Culture and Treatment of Ventricular Myocytes

Myocytes were dissociated from the ventricles of neonatal rat hearts(26) . The cells were preplated in DMEM/M199 (4:1 v/v) supplemented with 10% horse serum, 5% fetal calf serum, and 100 units/ml penicillin and streptomycin to remove fibroblasts. The myocytes, plated at a final density of 1.0 or 1.4 times 10^3 cells/mm^2 on gelatin-precoated 35-mm or 60-mm dishes, respectively, were confluent and spontaneously beating after 18 h. Serum was withdrawn for 24 h before the cells were further treated with either sorbitol (0.5 M), anisomycin (50 ng/ml), PMA (1 µM), ET-1 (100 nM), or phenylephrine (50 µM) in serum-free medium (DMEM/M199). For depletion of intracellular ATP, myocytes were incubated in KCN (1 mM) + DOG (20 mM) in serum-free medium(27, 28) . The effects of ATP repletion were examined after removal of KCN + DOG-containing medium, rinsing the cells twice in warmed serum-free medium, then further incubation in serum-free medium. Upon completion of the exposure protocol, the medium was aspirated and the cells washed twice in cold Ca/Mg-free Dulbecco's phosphate-buffered saline. Control experiments demonstrated that protein kinases were not activated by changes to serum-free medium only.

Solid-phase JNK Assays

Ventricular myocytes were scraped into 100 µl of Buffer A (20 mM HEPES, 2.5 mM MgCl(2), 0.1 mM EDTA, 20 mM beta-glycerophosphate, 0.05% (v/v) Triton X-100, 0.5 mM dithiothreitol (DTT), 0.1 mM Na(3)VO(4), 2 µg/ml leupeptin and 100 µg/ml phenylmethanesulfonyl fluoride, pH 7.7) containing 75 mM NaCl. Extracts were incubated on ice for 10 min, then centrifuged (10,000 times g, 10 min, 4 °C). Supernatants were added to 30 µg of GST-c-Jun(1-135). After incubation with continuous mixing at 4 °C for 2 h, glutathione-Sepharose (30 µl, 1:1 slurry in Buffer A containing 75 mM NaCl) was added and the incubation continued for 1 h at 4 °C. The pelleted glutathione-Sepharose was washed once in Buffer A containing 75 mM NaCl, once in Buffer B (20 mM HEPES, 75 mM NaCl, 2.5 mM MgCl(2), 0.1 mM EDTA, 20 mM beta-glycerophosphate, pH 7.7) containing 0.05% (v/v) Triton X-100, then in Buffer B.

The phosphorylation of GST-c-Jun(1-135) by protein kinases associated with the GST-c-Jun(1-135)/glutathione-Sepharose pellet was performed essentially as described(10) . The phosphorylation reaction was initiated with 30 µl of Kinase Buffer (20 mM HEPES, 20 mM MgCl(2), 20 mM beta-glycerophosphate, 2 mM DTT, 0.1 mM Na(3)VO(4), pH 7.6) containing 20 µM ATP and 1-2 µCi of [-P]ATP. After 20 min at 30 °C, the reaction was terminated by centrifugation and washing the pellet with cold Buffer B containing 0.05% (v/v) Triton X-100. Phosphorylated proteins in the pellet were eluted with boiling SDS-PAGE sample buffer (29) and separated by SDS-PAGE. Following staining with Coomassie Blue to detect the 46-kDa GST-c-Jun(1-135) and autoradiography, P incorporation into GST-c-Jun(1-135) was determined by Cerenkov counting.

Assay of JNK1 Immunocomplex Protein Kinase Activity

Myocytes were scraped into 150 µl of Buffer C (10 mM Tris/HCl, 5 mM EDTA, 50 mM NaF, 50 mM NaCl, 1% (v/v) Triton X-100, 0.1% (w/v) fatty acid-free bovine serum albumin, 20 µg/ml aprotinin, and 2 mM Na(3)VO(4), pH 7.4). After incubation on ice for 10 min, the lysate was centrifuged (10,000 times g, 10 min, 4 °C). Agarose-conjugated antibodies against the C terminus of JNK1 (1/30 dilution with supernatant) were added to the supernatants. After incubation with continuous mixing at 4 °C for 3 h, the pellets were washed three times in Buffer C, then twice in Buffer D (50 mM Tris/HCl, 0.1 mM EGTA, 0.5 mM Na(3)VO(4), and 0.1% (v/v) 2-mercaptoethanol, pH 8.0). The immunoprecipitates of JNK1 were resuspended in 30 µl of Kinase Buffer containing 20 µM ATP, 30 µg of GST-c-Jun(1-135), and 1-2 µCi of [-P]ATP. After 20 min at 30 °C with intermittent mixing, the reaction was terminated by centrifuging the immunoprecipitated kinases from the reaction mixture. An aliquot of the supernatant was mixed with SDS-PAGE sample buffer, boiled, and then separated by SDS-PAGE. Incorporation of P into GST-c-Jun(1-135) was determined by Cerenkov counting of the c-Jun band identified on Coomassie-stained gels.

In-gel Protein Kinase Assays

Activities of MBP kinases were assayed by the in-gel method(12, 13) . When the activities c-Jun(1-135) protein kinases were examined, 0.1 mg/ml GST-c-Jun(1-135) replaced MBP polymerized in the gel.

FPLC of c-Jun Kinases and MBP Kinases

Ventricular myocytes were lyzed in Buffer A. Extracts were incubated on ice for 10 min, then centrifuged (10,000 times g, 2 times 6 min, 4 °C). Supernatants were applied to a Mono Q HR5/5 column (Pharmacia) equilibrated with 50 mM Tris/HCl, 2 mM EDTA, 5% (v/v) glycerol, 0.3 mM Na(3)VO(4), pH 7.5 containing 0.1% (v/v) Triton X-100, 100 µg/ml phenylmethanesulfonyl fluoride, and 0.5 mM DTT at a flow rate of 1 ml/min. After washing with 5 ml of equilibration buffer, proteins were eluted with a linear gradient of 0-0.5 M NaCl. Fractions (1 ml) were collected and assayed immediately for phosphorylation of GST-c-Jun(1-135) or MBP. In these assays, 10 µl of each fraction was mixed with 20 µl of Kinase Buffer containing 20 µM ATP, 1 µCi of [-P]ATP, and either 30 µg of GST-c-Jun(1-135) or 15 µg of MBP. The reaction mixture was incubated at 30 °C for 30 min. JNK assays were terminated by the addition of SDS-PAGE sample buffer and incorporation of P into GST-c-Jun(1-135) was measured as by Cerenkov counting of the c-Jun band identified on Coomassie-stained gels. MBP kinase assays were terminated by pipetting 20 µl of the reaction mixture onto P81 paper, which was washed (3 times 10 min) in 75 mM H(3)PO(4). Incorporation of P into MBP was determined by Cerenkov counting of the phosphorylated MBP bound to P81.

Expression of Results

Throughout the text, the data presented are expressed as mean ± S.E. for the number of independent experiments (n) indicated. All experiments were performed on 2-8 independent occasions.


RESULTS

Activation of JNKs in Ventricular Myocytes

The ERK and JNK subfamilies of MAPKs phosphorylate Ser-63 and Ser-73 of the N-terminal transactivation domain of c-Jun in vitro(30) . ERKs do not bind c-Jun with high affinity (10, 31) and JNKs may be responsible for phosphorylation of c-Jun in vivo(22) . We used a solid-phase kinase assay (10) to identify protein kinases that bind to and phosphorylate the N-terminal domain of c-Jun.

Exposure of ventricular myocytes to 0.5 M sorbitol or 50 ng/ml anisomycin produced 2-5-fold changes in JNK activity after 5 min, and this increased to 10-20-fold changes after 15-30 min (Fig. 1A). Activation of JNK by these agonists was also observed in cells that had not been serum-starved (results not shown). ET-1 (100 nM) activated JNK, but maximal activation (5-fold) was less than with sorbitol or anisomycin (Fig. 1A). PMA (1 µM) did not activate JNK (Fig. 1A). Pretreatment with PMA (1 µM, 24 h), which depletes the classical (c) and novel (n) PKC isoforms of these cells (13) , did not affect activation of JNKs by sorbitol (results not shown), indicating a cPKC/nPKC-independent pathway of activation.


Figure 1: Activation of JNKs in cultured neonatal rat ventricular myocytes. A, time course for the activation of JNK. Individual 35-mm dishes of ventricular myocytes were exposed to 0.5 M sorbitol (bullet), 50 ng/ml anisomycin (box), 1 µM PMA (), 100 nM ET-1 (), or serum-free control medium (circle). Extracts were assayed for JNK activity using the solid-phase JNK assay described under ``Experimental Procedures.'' JNK activities (mean ± S.E., n = 3-8 independent observations, except for 120, 180, and 240 min where n = 2) are expressed relative to the activities in untreated cells. B, comparison of the effect of sorbitol and ET-1 on JNK activation. Individual 35-mm dishes of ventricular myocytes were exposed to 0.5 M sorbitol or 100 nM ET-1. Extracts were assayed for JNK activity by the in-gel protein kinase assay using 0.1 mg/ml GST-c-Jun(1-135) polymerized in 10% SDS-PAGE gels as described under ``Experimental Procedures.'' The molecular masses (kDa) of marker proteins are indicated by the numbers to the left of the panel. The arrows indicate the positions of the 55- and 46-kDa JNKs (JNK-55 and JNK-46, respectively).



The time course of JNK activation was examined (Fig. 1A). Activation of JNK by sorbitol was sustained during a 4-h exposure (Fig. 1A). This activation following osmotic shock contrasted with the transient activation of JNK following osmotic shock of HeLa cells (32) or the exposure of other cell types to UV stress(8) , carbachol (33) , interleukin-1(32) , or tumor necrosis factor-alpha(34) . Activation of JNK in myocytes by anisomycin or ET-1 was transient, being reversed after 180-240 min (Fig. 1A).

The protein kinases that phosphorylate GST-c-Jun(1-135) were characterized by in-gel kinase assays. No activity was detected in extracts of untreated cells (Fig. 1B) or when GST-c-Jun(1-135) was omitted from the gels (results not shown). Following exposure to sorbitol or ET-1 for 5 min, two protein kinases with molecular masses of 46 kDa (JNK-46) and 55 kDa (JNK-55) were detected (Fig. 1B). The JNK-55 band was less intense than JNK-46. Activation of both JNKs followed a similar time course and, in agreement with solid-phase JNK assays (Fig. 1A), the activation by sorbitol was at least 3-fold greater than the activation by ET-1. The molecular masses of these JNKs agree with those for renaturable JNKs previously described(8, 10, 35) .

Differential Activation of JNKs and ERKs by PMA

The cis-acting AP-1 element through which c-Fos/c-Jun dimers transactivate was originally recognized by its sensitivity to activation by PMA(36, 37) . The mechanisms involved in PMA activation at AP-1 sites have not yet been fully elucidated. PMA activates JNKs in Jurkat cells (10) but not in HeLaS3 (10, 22, 32) or NIH 3T3 cells(33) . The reasons for this difference have not been clarified. In ventricular myocytes, PMA does not activate JNK in solid-phase kinase assays (Fig. 1A). PMA activates ERK1 and ERK2 in myocytes(12, 13, 38) and in other cells (39, 40) and these kinases also phosphorylate Ser-63 and Ser-73 of c-Jun(7) . We therefore studied the extent to which PMA activated non-JNK GST-c-Jun(1-135) kinases by comparing it with anisomycin after a 30-min exposure.

Total extracts of ventricular myocytes exposed to 1 µM PMA were examined by in-gel kinase assays using either GST-c-Jun(1-135) (Fig. 2A) or MBP (Fig. 2B). PMA activated two protein kinases of 42 and 44-46 kDa when either MBP or GST-c-Jun(1-135) was the substrate. The ability of the 42- and 44-46-kDa protein kinases to phosphorylate MBP (Fig. 2B) suggests that ERK1 and ERK2 rather than JNKs are responsible for the GST-c-Jun(1-135) phosphorylation. The finding that PMA did not activate JNKs using solid-phase assays (Fig. 1A) supports this conclusion. However, when total extracts of PMA-treated myocytes were incubated with GST-c-Jun(1-135) and [-P]ATP, GST-c-Jun(1-135) phosphorylation was detectable (results not shown), confirming that PMA-activated non-JNK GST-c-Jun(1-135) kinases are present in extracts. Others have shown that ERKs copurify with phorbol ester-activated c-Jun kinases (41) , supporting the conclusion that both ERKs and JNKs phosphorylate the transactivation domain of c-Jun.


Figure 2: PMA activates ERK1 and ERK2 but anisomycin activates JNK-46 and JNK-55. Individual 35-mm dishes of ventricular myocytes were exposed to 1 µM PMA or 50 ng/ml anisomycin for the times indicated at the bottom of each panel. Extracts were assayed by in-gel kinase assays using 0.1 mg/ml GST-c-Jun(1-135) (A) or 0.5 mg/ml MBP (B) polymerized in 10% SDS-PAGE gels as described under ``Experimental Procedures.'' Each gel is representative of two independent experiments. The molecular masses (kDa) of marker proteins are indicated by the numbers to the left of each panel. The arrows indicate the positions of the protein kinase activities that change upon exposure to PMA or anisomycin. In A, these migrate at 55, 44-46, and 42 kDa; in B, they migrate at 44-46 and 42 kDa.



It has been suggested that PMA activates JNKs in T cells only when Ca influx is stimulated. Thus, PMA and the Ca ionophore A23187 synergistically stimulate JNK activity(35) . This finding could be relevant to our failure to observe activation of JNKs by PMA (Fig. 1A and 2A). However, simultaneous exposure of ventricular myocytes to PMA (1 µM) and the Ca ionophore, ionomycin (0.1 µM) did not activate JNKs as assayed by in-gel GST-c-Jun(1-135) kinase assays (results not shown).

In contrast to PMA, anisomycin (50 ng/ml) activated JNK-46 and JNK-55 (Fig. 2A). The JNK-55 band was less intense than that for JNK-46. Anisomycin only weakly activated ERK1 and ERK2 as shown by in-gel phosphorylation of MBP (Fig. 2B).

Differential Activation of JNKs and ERKs by Sorbitol and Phenylephrine

The activation of ERKs and JNKs in ventricular myocytes by 0.5 M sorbitol or 50 µM phenylephrine was compared with that by 50 ng/ml anisomycin or 1 µM PMA after 30 min of exposure (Fig. 3). Like PMA, phenylephrine is an hypertrophic agonist that activates ERK1 and ERK2(12, 13) . The activation of ERK1 and ERK2 by PMA and phenylephrine was confirmed using in-gel assays with MBP (Fig. 3A). Sorbitol (but not anisomycin) stimulated the activities of ERK1 and ERK2 (Fig. 3A). Sorbitol also reduced the mobility of both ERK isoforms (indicating their phosphorylation; (26) ) as assessed by SDS-PAGE and immunoblotting with anti-ERK1/ERK2 antiserum (23) (results not shown). In-gel kinase assays using GST-c-Jun(1-135) demonstrated the activation of JNK-46 and JNK-55 by sorbitol and anisomycin (Fig. 3B). In-gel GST-c-Jun(1-135) kinase assays following precipitation of JNKs interacting with GST-c-Jun(1-135) using GSH-Sepharose confirmed that both JNK-46 and JNK-55 were activated by sorbitol or anisomycin (Fig. 3C).


Figure 3: Activation of ERKs and JNKs by sorbitol and phenylephrine. Individual 35-mm dishes of ventricular myocytes were exposed to serum-free medium (CON), 0.5 M sorbitol (SRB), 50 ng/ml anisomycin (AN), 1 µM PMA, or 50 µM phenylephrine (PE) in serum-free medium (DMEM/M199) for 30 min. Extracts were prepared then resuspended in SDS-PAGE sample buffer (panels A and B) or subjected to the solid-phase JNK assay up to the glutathione-Sepharose precipitation step (panel C) as described under ``Experimental Procedures.'' The pellets from the solid-phase assay glutathione-Sepharose precipitation step (panel C) were then resuspended in SDS-PAGE buffer. A, activation of MBP kinases was assayed by the in-gel kinase method using 0.5 mg/ml MBP polymerized in 10% SDS-PAGE gels as described under ``Experimental Procedures.'' B and C, activation of JNKs was assayed by the in-gel kinase method using 0.1 mg/ml GST-c-Jun(1-135) polymerized in 10% SDS-PAGE gels as described under ``Experimental Procedures.'' Each gel is representative of two independent experiments. The molecular masses (kDa) of marker proteins are indicated by the numbers to the left of each panel. The arrows indicate the positions of the protein kinase activities that change upon exposure to sorbitol, anisomycin, PMA, or phenylephrine. In A, these migrate at 44-46 and 42 kDa; in B, they migrate at 55, 44-46, and 42 kDa; in C, they migrate at 55 and 44-46 kDa.



As described above, PMA activated two GST-c-Jun(1-135) kinases that appeared to correspond with ERK1 and ERK2 (Fig. 3, compare A and B). These kinases were not recovered in the GSH-Sepharose pellet following interaction with GST-c-Jun(1-135) (Fig. 3C), but remained in the supernatant (results not shown). This is consistent with the weaker interaction of ERKs with the N terminus of c-Jun(31) . Using PMA-activated GST-c-Jun(1-135) kinases as markers, it can be concluded that the weaker activation of a GST-c-Jun(1-135) kinase at about 42 kDa by sorbitol (Fig. 3B) may be attributable to ERK2. Any GST-c-Jun(1-135) kinase activity stimulated by sorbitol attributable to ERK1 is obscured by activation of JNK-46 (Fig. 3B). Phenylephrine (50 µM) only very weakly activated GST-c-Jun(1-135) kinases (Fig. 3B) and again, based on their migration relative to PMA-stimulated GST-c-Jun(1-135) kinases, these activities were probably attributable to ERK1 and ERK2. However, weak activation of JNK1 and JNK2 by phenylephrine was detected by in-gel phosphorylation of GST-c-Jun(1-135) following precipitation of JNKs interacting with GST-c-Jun(1-135) with GSH-Sepharose (Fig. 3C).

JNK-46 Is Recognized by an Antibody against Human JNK-1

The identity of c-Jun protein kinases in ventricular myocytes with previously characterized c-Jun kinases (JNK-1 and JNK-2 in the human; or stress-activated protein kinase (SAPK)alphaI, SAPKalphaII, SAPKbeta, SAPK in the rat) was investigated using an antibody directed against the C terminus of the human 46-kDa JNK1 (the human homologue of rat SAPK). An immunoprecipitation protocol using this agarose-conjugated antibody showed that 0.5 M sorbitol or 50 ng/ml anisomycin activated protein kinases immunologically related to JNK1 by 6-8-fold after 15 min of exposure (results not shown) or 8-10-fold after 30 min (Fig. 4A). ET-1 (100 nM) also activated this protein kinase by 2-4-fold. Any activation by 50 µM phenylephrine was very weak. Preliminary experiments showed that immunoprecipitation was complete because a second incubation with agarose-linked antibody did not remove any further JNK activity (results not shown). Specificity of interaction was established by the finding that inclusion of the immunizing peptide prevented immunoprecipitation of JNK activity from sorbitol- or anisomycin-stimulated cells (results not shown). In-gel GST-c-Jun(1-135) kinase assays showed that the immunoprecipitation method measured activation of JNK-46 (Fig. 4B). JNK-55 was not recognized by the anti-JNK1 antibody and remained in the supernatant (Fig. 4B).


Figure 4: Immunoprecipitation of activated JNK by an anti-JNK1 antibody. Individual 60-mm dishes of ventricular myocytes were exposed to control serum-free medium, 0.5 M sorbitol (SRB), 50 ng/ml anisomycin (AN), 1 µM PMA, 50 µM phenylephrine (PE), or 100 nM ET-1 for 30 min. Extracts were prepared, then subjected to immunocomplex GST-c-Jun(1-135) kinase assays using an agarose-conjugated anti-JNK1 antibody as described under ``Experimental Procedures.'' A, JNK activities (means ± S.E., n = 4-5 independent observations) are expressed relative to activities in control cells. B, the pellets and supernatants from the immunoprecipitation step of the immunocomplex kinase assays were resuspended in SDS-PAGE buffer and activation of JNKs was assayed by the in-gel kinase method using 0.1 mg/ml GST-c-Jun(1-135) polymerized in 10% SDS-PAGE gels as described under ``Experimental Procedures.'' The molecular masses (kDa) of marker proteins are indicated by the numbers to the left of the panel. The arrows indicate the positions of the protein kinase activities that change upon exposure to sorbitol or anisomycin. These migrate at 55 or 46 kDa.



FPLC of GST-c-Jun(1-135) Kinases Stimulated after Exposure to Sorbitol or PMA

Activation of GST-c-Jun(1-135) kinases by exposure to 0.5 M sorbitol was greater than that observed for other agonists (Fig. 1A, and Fig. 3, B and C). Sorbitol-activated GST-c-Jun(1-135) kinases were further characterized by FPLC on Mono Q columns (Fig. 5A). Three peaks of activity (J1 eluting in the isocratic wash, J2 eluting at 100-150 mM NaCl, and J3 eluting at 200-250 mM NaCl) were stimulated. No further GST-c-Jun(1-135) kinase activities were eluted at NaCl concentrations up to 1 M (results not shown). Fractions were concentrated by 20-40-fold and were further analyzed by in-gel GST-c-Jun(1-135) kinase assays (Fig. 5B). Pooled fractions (i) (Fig. 5A) contained a 44-kDa GST-c-Jun(1-135) kinase, pooled fractions (ii) contained a 46-kDa kinase, pooled fractions (iii) contained 46- and 55-kDa kinases, and pooled fractions (iv) contained a 55-kDa kinase (Fig. 5B). As demonstrated by solid-phase kinase assays, activities from peaks J1, J2, and J3 (Fig. 5A) associated with GST-c-Jun(1-135) (results not shown). We also separated extracts of PMA-treated myocytes by FPLC on MonoQ. Only two peaks of PMA-stimulated c-Jun kinase activity were detected (Fig. 5C). These appeared to correspond with region iv (peak J3) from sorbitol-treated myocytes (Fig. 5A). PMA did not stimulate c-Jun kinases corresponding to regions J1 or J2 (Fig. 5C). These results confirm the limited activation of the JNKs by PMA and that no novel c-Jun kinases were activated after PMA exposure.


Figure 5: Activation of c-Jun kinases by sorbitol or PMA. A, five 60-mm dishes of ventricular myocytes were exposed to control serum-free medium (circle) or 0.5 M sorbitol (bullet) for 30 min. Extracts were prepared and proteins separated by FPLC using a Mono Q column with elution by a linear NaCl gradient (dotted line). Fractions were assayed for JNK activity as described under ``Experimental Procedures.'' The peaks of JNK activity are labeled J1, J2, and J3. B, FPLC Mono Q column fractions from sorbitol-treated myocytes were pooled as indicated (i-iv), concentrated and assayed by the in-gel kinase method using 0.1 mg/ml GST-c-Jun(1-135) polymerized in 10% SDS-PAGE gels as described under ``Experimental Procedures''. The molecular masses (kDa) of marker proteins are indicated by the numbers to the left of the panel. C, five 60-mm dishes of ventricular myocytes were exposed to control serum-free medium (circle) or 1 µM PMA () for 5 min. Extracts were prepared and proteins separated by FPLC using a Mono Q column with elution by a linear NaCl gradient (dotted line). Fractions were assayed for JNK activity.



FPLC fractions from sorbitol-treated myocytes were also assayed for MBP kinases (Fig. 6A). Only a single asymmetric peak of MBP kinase was observed (M1, Fig. 6A). Although peaks M1 and J3 (Fig. 5A) overlapped, peak J3 consistently preceded peak M1 by 1 to 2 fractions (n = 3 separate occasions, compare Fig. 5A and Fig. 6A). MBP kinases of 55, 44, and 42 kDa were detected in pooled fractions (iv) (Fig. 5B). (The autoradiograph has been overexposed to demonstrate the limited renaturable MBP kinase present in pooled fractions (i-iii)). The 55-kDa MBP kinase may possibly correspond to a JNK-55 isoform in pooled fractions (iv). The other JNK isoforms, including the 55-kDa isoform in pooled fractions (iii) and the 46-kDa isoform in pooled fractions (ii), do not utilize MBP as a substrate (Fig. 6B).


Figure 6: Activation of MBP kinases by sorbitol or PMA. A, FPLC Mono Q column fractions prepared from ventricular myocytes exposed to control serum-free medium (circle) or 0.5 M sorbitol (bullet) for 30 min as described in the legend to Fig. 5were assayed for MBP kinase activity. B, FPLC Mono Q column fractions from sorbitol-treated myocytes were pooled as indicated (i-iv), concentrated, and assayed by the in-gel kinase method using 0.5 mg/ml MBP polymerized in 10% SDS-PAGE gels as described under ``Experimental Procedures.'' The molecular masses (kDa) of marker proteins are indicated by the numbers to the left of the panel. C, FPLC Mono Q column fractions prepared from ventricular myocytes exposed to control serum-free medium (circle) or 1 µM PMA () for 5 min as described in the legend to Fig. 5were assayed for MBP kinase activity.



As shown by immunoblotting of pooled fractions (iv) with anti-ERK1/ERK2 antiserum(24) , the 42- and 44-kDa MBP kinases correspond to ERK2 and ERK1, respectively (results not shown). We also separated extracts of PMA-treated myocytes by FPLC on MonoQ (Fig. 6C). Two peaks of PMA-stimulated MBP kinase activity were detected (Fig. 6C). These peaks co-elute with the PMA-stimulated c-Jun kinases (Fig. 5C). Thus, PMA appears to stimulate the ERKs in the absence of significant JNK activation.

Activation of JNKs by Sorbitol Is Reversible

The mechanism of activation of JNKs by stress is unknown but may involve signaling via Ras (6, 8) and/or MEKK1(42, 43) . The mechanisms of inactivation of the cascade have not been examined extensively. Inactivation may involve the protein phosphatase MKP-1 (44) that was originally identified as immediate-early gene product induced after exposure of cells to heat shock or oxidative stress (reviewed in (45) ), but that was subsequently demonstrated to be a dual-specificity Thr/Tyr-phosphatase acting upon ERK1 and ERK2(46) . Because the activation of JNKs by sorbitol was potent and sustained (Fig. 1A), we examined whether this activation was reversible, or whether irreversible cell damage that may occur under conditions of high osmotic stress induces irreversible activation of the enzymes.

We examined the time course of inactivation of JNK-46 in the ventricular myocyte following activation by 0.5 M sorbitol. Cells were treated with sorbitol for 15 min, and then followed by incubation with serum-free medium for 15, 45, or 60 min. Immunocomplex kinase assays (which detect principally JNK-46; Fig. 4B) demonstrated that JNK-46 was inactivated within 15-45 min of removal of sorbitol (Fig. 7). The inactivation of both JNK-46 and JNK-55 was confirmed using the in-gel GST-c-Jun(1-135) kinase assays (results not shown). These results suggest that sorbitol provides a potent and prolonged stimulation of the signaling pathway leading to activation of JNKs, and that JNKs can be rapidly inactivated after removal of the positive signaling components.


Figure 7: Activation of JNKs by sorbitol is reversible. Individual 60-mm dishes of ventricular myocytes were exposed to serum-free medium or 0.5 M sorbitol for 15 min. The medium was then aspirated and the cells exposed to either serum free-medium (circle, dashed line) or 0.5 M sorbitol (bullet, solid line). Extracts were prepared then subjected to immunocomplex GST-c-Jun(1-135) kinase assays using an agarose-conjugated anti-JNK1 antibody as described under ``Experimental Procedures.'' This method principally assays JNK-46. JNK-46 activities (means ± S.E., n = three independent observations) are expressed relative to the activities in control cells.



ATP Depletion/Repletion Activates the ERKs in the Absence of JNK

The ventricular myocyte may be exposed to cellular stresses, such as myocardial ischemia and the reperfusion of an ischemic region (18, 19) . Ischemia leads to osmotic imbalance and odema(47) ; reperfusion of the ischemic areas then leads to the formation of highly reactive free radicals and oxidative cell stress(48) . Although the myocytes in the ischemic region may die, those bordering on this zone may increase in size to compensate for the lost contractile capacity (18, 20) .

An in vitro tissue culture model of ischemia is the inhibition of ATP synthesis by exposure of myocytes to KCN+DOG(28, 49) . Recently it has been shown that ERKs are activated during the recovery from metabolic inhibition(28) . We exposed ventricular myocytes to concentrations of cyanide and DOG previously demonstrated to deplete intracellular ATP concentrations in these cultured cells (27) . Cytosolic extracts were analyzed using the in-gel method for activation of JNKs (Fig. 8A). Neither JNK-46 or JNK-55 were activated by up to 120 min of exposure to cyanide and DOG (Fig. 8A). Furthermore, the removal of cyanide and DOG also did not activate the JNKs (Fig. 8B). Weak kinase bands of 42 and 44 kDa were detected (Fig. 8, A and B), and these appeared to correspond to the ERKs in MBP-containing gels (Fig. 8, C and D). Thus, different forms of cellular stress may activate different MAPK signaling cascades.


Figure 8: Exposure to cyanide and deoxyglucose and the subsequent removal of cyanide and deoxyglucose from the medium activates ERKs. Individual 35-mm dishes of ventricular myocytes were exposed to medium containing 1 mM KCN + 20 mM DOG for 5-120 min or to medium containing sorbitol (SRB) for 30 min. In panels B and D, the myocytes were exposed to KCN+DOG for 60 min, then exposed to fresh serum-free medium for a further 5 to 60 min. Extracts were prepared, then analyzed by the in-gel kinase method using 0.1 mg/ml GST-c-Jun(1-135) (A and B) or 0.5 mg/ml MBP (C and D) polymerized in 10% SDS-PAGE gels as described under ``Experimental Procedures.'' Each gel is representative of two independent experiments. The molecular masses (kDa) of marker proteins are indicated.




DISCUSSION

Signal Transduction following Exposure to Cellular Stress

The signal transduction pathways that alter gene transcription following cellular stress remain unresolved. Although UV irradiation was thought to act directly on the cell nucleus, activation of cytoplasmic protein kinase cascades has now been demonstrated(50) . Two protein kinases, JNK1 and JNK2, are activated within 5 min of exposure to UV irradiation (10) .

The JNKs, members of the MAPK family, are activated by phosphorylation of Thr and Tyr in a conserved Thr-Pro-Tyr sequence (reviewed in (51) ). JNK activity in the ventricular myocyte can be separated into three peaks by FPLC on Mono Q (Fig. 5A) that elute at a lower NaCl concentration than ERKs (Fig. 6, A and C). The relationship between the 44-kDa GST-c-Jun(1-135) kinase identified by FPLC on Mono Q (peak J1 in Fig. 5A) and JNK-46/JNK-55 requires further investigation. One form of the JNKs in the ventricular myocyte (JNK-46) was recognized by JNK1-specific antisera (Fig. 4, A and B). JNK-55 is presumably related to JNK-2.

Although the upstream signaling events remain unresolved, it has become clear that diverse signals, including inflammatory cytokines(9, 52) , protein synthesis inhibitors ( (53) and Fig. 1), ischemic reperfusion (54) , and osmotic stress ( (55) and Fig. 1), activate the JNK subfamily of MAPKs. The activation of the ERK subfamily of MAPKs is better understood and is mediated through receptor protein tyrosine kinases or G-protein-coupled receptors(56) . In the heart, ET-1 and phenylephrine stimulate ERK activities, and this probably involves a Galpha(q)-mediated activation of PKC(13, 26, 57) . Thus PMA also strongly activates ERKs in heart(12, 13, 38) . It was of interest to study whether ET-1, phenylephrine, and PMA activated JNKs, and equally whether activators of JNKs (sorbitol and anisomycin) activated ERKs. Phenylephrine and PMA, although potent ERK activators (Fig. 2B and Fig. 3A), were the least effective of the JNK activators tested (Fig. 1A, 2A, 3 (B and C), 4A, and 5C). Sorbitol was the most potent activator of JNKs ( Fig. 1(A and B) and 3 (B and C)) and also activated ERKs (Fig. 3A and Fig. 6(A and B)). Anisomycin was a poor activator of ERKs in comparison to sorbitol or PMA (Fig. 2B and Fig. 3A). Interestingly, ET-1 was a moderately effective activator of JNKs (Fig. 1A and Fig. 4A), as well as a powerful activator of ERKs(12, 13, 26, 57) . Intracellular signaling by ET-1 involves both Galpha(q)- and Galpha(i)-coupled pathways(58, 59) . JNKs can be activated by a Galpha(q)-dependent pathway activated by the m(1)-muscarinic agonist carbachol (33) or by constitutively activated Galpha or Galpha. The JNKs therefore can be activated by G-protein-dependent pathways in addition to cell stress, although this may be cell- and agonist-specific.

It is important to understand the extent of cross-talk between the JNK and ERK pathways, given that an increase in the transactivating activity of c-Jun may be an end response of activation of both pathways. Although activation of ERKs by ET-1, phenylephrine or PMA in ventricular myocytes is maximal at 5 min(13) , the maximal activation of JNKs by any agonist (including ET-1) was slower, being maximal at 30-60 min ( Fig. 1(A and B) and 2 (A and B)). If the ERK and JNK pathways are parallel as suggested (51, 60) with c-Jun as a common substrate, the mechanisms leading to differential rates of activation of each pathway must be identified. This is particularly pertinent when a single agonist (e.g. ET-1 or sorbitol) is able to activate ERKs and JNKs.

Sorbitol produced sustained activation of the JNKs in ventricular myocytes (Fig. 1, A and B, and Fig. 7). This was not the result of an irreversible event, as the removal of sorbitol from the medium led to rapid inactivation of the JNKs (Fig. 7). We have been unable to detect activities of the homologues of the osmoregulatory S. cerevisiae HOG-1 protein kinase pathway in neonatal rat ventricular myocytes. (^3)

Pathophysiological Relevance of the JNK Pathway

Several studies have demonstrated that myocyte hypertrophy occurs following cardiac stress (ischemia, ischemia-reperfusion, hypertension)(18, 19, 20, 61, 62, 63) . Pathological hypertrophy involves a number of well characterized changes in gene expression(1) , which are presumably mediated at the level of the nucleus through changes in the transactivating activities of transcription factors. Although neurohumoral factors cannot be discounted in the development of hypertrophy, a number of events may occur to impose cell stress and these may also be important in the hypertrophic response. Stresses include the generation of free radicals, osmotic imbalances, hypoxia, metabolic inhibition, metabolite accumulation, and changes in ion handling(64, 65, 66) . Our results suggest that activation of JNKs may be triggered by osmotic stress on ventricular myocytes, although metabolic inhibition by cyanide and DOG activated the ERKs in the absence of JNK activation (Fig. 8). We have recently shown that the JNKs, although not activated in ischemic heart are activated upon reperfusion. (^4)The response of the myocyte to cellular stress is therefore complex. In an in vivo setting, it may be that parallel MAPKs are activated to produce the complete response to ischemia or the damage that follows during reperfusion of the ischemic area. The phenomenon of ischemic preconditioning, in which a short period of myocardial ischemia protects against a subsequent ischemic episode, may involve protein kinase activation (67) and parallel MAPK pathways may be important.

This study has shown that the ventricular myocyte is able to respond to cellular stress by differential activation of the JNK or ERK pathways. The ventricular myocyte in primary culture thus serves as a useful model for studying the responses to cellular stress. The exact phenotypic consequences of the JNK activation pathway must be defined by introduction of constitutively active forms of JNKs or their upstream activators (68, 69, 70) into these cells.


FOOTNOTES

*
This work was supported principally by grants from The Wellcome Trust, the British Heart Foundation, and the Clinical Research Committee of the Royal Brompton Hospital, London. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Present address: CRC Centre for Cell and Molecular Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Rd., London SW3 6JB, United Kingdom.

(^1)
The abbreviations used are: AP-1, activator protein-1; DMEM, Dulbecco's modified Eagle's medium; DOG, 2-deoxy-D-glucose; DTT, dithiothreitol; ERK, extracellular signal-regulated (protein) kinase; ET-1, endothelin-1; FPLC, fast protein liquid chromatography; GST, glutathione S-transferase; JNK, c-Jun N-terminal protein kinase; M199, medium 199; MAPK, mitogen-activated protein kinase; MEK, MAPK (or ERK) kinase; MBP, myelin basic protein; PAGE, polyacrylamide gel electrophoresis; PMA, phorbol 12-myristate 13-acetate; SAPK, stress activated protein kinase; PKC, protein kinase C.

(^2)
We use the term mitogen-activated protein kinase (MAPK) for the family of kinases that includes the extracellular signal-regulated (protein) kinase (ERK) subfamily and the c-Jun N-terminal kinase (JNK) subfamily. ERK1 and ERK2 are also known as p44 and p42, respectively. JNKs are also known as stress-activated protein kinases (SAPKs). The MAPK family also includes protein kinases that are related to the Saccharomyces cerevisiae HOG-1 osmoregulatory protein kinases.

(^3)
M. A. Bogoyevitch, A. J. Ketterman, and P. H. Sugden, unpublished observations.

(^4)
M. A. Bogoyevitch, J. Gillespie-Brown, A. J. Ketterman, S. J. Fuller, R. Ben-Levy, A. Ashworth, C. J. Marshall, and P. H. Sugden, submitted for publication.


ACKNOWLEDGEMENTS

We thank Nicola J. Haward for the preparation of myocyte cultures.


REFERENCES

  1. Chien, K. R., Knowlton, K. U., Zhu, H., and Chien, S. (1991) FASEB J. 5, 3037-3046 [Abstract/Free Full Text]
  2. Sadoshima, J.-I., and Izumo, S. (1993) Circ. Res. 73, 424-438 [Abstract]
  3. Treisman, R. (1994) Curr. Opin. Genet. & Dev. 4, 96-101 [Medline] [Order article via Infotrieve]
  4. Marais, R., Wynne, J., and Treisman, R. (1993) Cell 73, 381-393 [Medline] [Order article via Infotrieve]
  5. Chiu, R., Boyle, W. J., Meek, J., Smeal, T., Hunter, T., and Karin, M. (1988) Cell 54, 541-552 [Medline] [Order article via Infotrieve]
  6. Binetruy, B., Smeal, T., and Karin, M. (1991) Nature 351, 122-127 [CrossRef][Medline] [Order article via Infotrieve]
  7. Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E., and Woodgett, J. R. (1992) Nature 353, 670-673
  8. Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037 [Medline] [Order article via Infotrieve]
  9. Bird, T. A., Kyriakis, J. M., Tyshler, L., Gayle, M., Milne, A., and Virca, G. D. (1994) J. Biol. Chem. 269, 31836-31844 [Abstract/Free Full Text]
  10. Hibi, M., Lin, A., Smeal, T., Minden, A., and Karin, M. (1994) Genes & Dev. 7, 2135-2148
  11. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994) Nature 369, 156-160 [CrossRef][Medline] [Order article via Infotrieve]
  12. Bogoyevitch, M. A., Glennon, P. E., and Sugden, P. H. (1993) FEBS Lett. 317, 271-275 [CrossRef][Medline] [Order article via Infotrieve]
  13. Bogoyevitch, M. A., Glennon, P. E., Andersson, M. B., Clerk, A., Lazou, A., Marshall, C. J., Parker, P. J., and Sugden, P. H. (1994) J. Biol. Chem. 269, 1110-1119 [Abstract/Free Full Text]
  14. Thorburn, A., Thorburn, J., Chen, S.-Y., Powers, S., Shubeita, H. E., Feramisco, J. R., and Chien, K. R. (1993) J. Biol. Chem. 268, 2244-2249 [Abstract/Free Full Text]
  15. Thorburn, J., McMahon, M., and Thorburn, A. (1994) J. Biol. Chem. 269, 30580-30586 [Abstract/Free Full Text]
  16. Sugden, P. H., Gillespie-Brown, J., Fuller, S. J., Cowley, S., Ashworth, A., and Marshall, C. J. (1994) Circulation 90, I-303 (abstr.)
  17. Thorburn, J., Frost, J. A., and Thorburn, A. (1994) J. Cell Biol. 126, 1565-1572 [Abstract]
  18. Gerdes, A. M., Kellerman, S. E., Moore, J. A., Muffly, K. E., Clark, L. C., Reaves, P. Y., Malec, K. B., McKeown, P. P., and Schocken, D. D. (1992) Circulation 86, 426-430 [Abstract]
  19. Anversa, P., Beghi, C., Kikkawa, Y., and Olivetti, G. (1986) Circ. Res. 58, 26-37 [Abstract]
  20. Olivetti, G., Capasso, J. M., Meggs, L. G., Sonnenblick, E. H., and Anversa, P. (1991) Circ. Res. 68, 856-869 [Abstract]
  21. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  22. Kallunki, T., Su, B., Tsigelny, I., Sluss, H. K., Dérijard, B., Moore, G., Davis, R., and Karin, M. (1994) Genes & Dev. 8, 2996-3007
  23. Leevers, S. J., and Marshall, C. J. (1992) EMBO J. 11, 569-574 [Abstract]
  24. Stokoe, D., Campbell, D. G., Nakielny, S., Hidaka, H., Leevers, S. J., Marshall, C., and Cohen, P. (1992) EMBO J. 11, 3985-3994 [Abstract]
  25. Alessi, D. R., Saito, Y., Campbell, D. G., Cohen, P., Sithanandam, G., Rapp, U., Ashworth, A., Marshall, C. J., and Cowley, S. (1994) EMBO J. 13, 1610-1619 [Abstract]
  26. Clerk, A., Bogoyevitch, M. A., Andersson, M. B., and Sugden, P. H. (1994) J. Biol. Chem. 269, 32848-32857 [Abstract/Free Full Text]
  27. Webster, K. A., Discher, D. J., and Bishopric, N. H. (1994) Circ. Res. 74, 679-686 [Abstract]
  28. Yao, A., Takahashi, T., Aoyagi, T., Kinugawa, K., Kohmoto, O., Sugiura, S., and Serizawa, T. (1995) J. Clin. Invest. 96, 69-77 [Medline] [Order article via Infotrieve]
  29. Bogoyevitch, M. A., Parker, P. J., and Sugden, P. H. (1993) Circ. Res. 72, 757-767 [Abstract]
  30. Alvarez, E., Northwood, I. C., Gonzalez, F. A., Latour, D. A., Seth, A., Abate, C., Curran, T., and Davis, R. J. (1991) J. Biol. Chem. 266, 15277-15285 [Abstract/Free Full Text]
  31. Gupta, S., and Davis, R. J. (1994) FEBS Lett. 353, 281-285 [CrossRef][Medline] [Order article via Infotrieve]
  32. Raingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) J. Biol. Chem. 270, 7420-7426 [Abstract/Free Full Text]
  33. Coso, O. A., Chiariello, M., Kalinec, G., Kyriakis, J. M., Woodgett, J., and Gutkind, J. S. (1995) J. Biol. Chem. 270, 5620-5624 [Abstract/Free Full Text]
  34. Sluss, H. K., Barrett, T., Dérijard, B., and Davis, R. J. (1994) Mol. Cell. Biol. 14, 8376-8384 [Abstract]
  35. Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M., and Ben-Neriah, Y. (1994) Cell 77, 727-736 [Medline] [Order article via Infotrieve]
  36. Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., and Karin, M. (1987) Cell 49, 729-739 [Medline] [Order article via Infotrieve]
  37. Lee, W., Mitchell, P. J., and Tijan, R. (1987) Cell 49, 741-752 [Medline] [Order article via Infotrieve]
  38. Lazou, A., Bogoyevitch, M. A., Clerk, A., Fuller, S. J., Marshall, C. J., and Sugden, P. H. (1994) Circ. Res. 75, 932-941 [Abstract]
  39. Adams, P. D., and Parker, P. J. (1991) FEBS Lett. 290, 77-82 [CrossRef][Medline] [Order article via Infotrieve]
  40. Tobe, K., Kadowaki, T., Tamemoto, H., Ueki, K., Hara, K., Koshio, O., Momomura, K., Gotoh, Y., Nishida, E., Akanuma, Y., Yazaki, Y., and Kasuga, M. (1991) J. Biol. Chem. 266, 24793-24803 [Abstract/Free Full Text]
  41. Pulverer, B. J., Hughes, K., Franklin, C. C., Kraft, A. S., Leevers, S. J., and Woodgett, J. R. (1993) Oncogene 8, 407-415 [Medline] [Order article via Infotrieve]
  42. Yan, M., Dai, T., Deak, J. C., Kyriakis, J. M., Zon, L. I., Woodgett, J. R., and Templeton, D. J. (1994) Nature 372, 798-800 [Medline] [Order article via Infotrieve]
  43. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Dérijard, B., Davis, R. J., Johnson, G. L., and Karin, M. (1994) Science 266, 1719-1723 [Medline] [Order article via Infotrieve]
  44. Liu, Y., Gorospe, M., Yang, C., and Holbrook, N. J. (1995) J. Biol. Chem. 270, 8377-8380 [Abstract/Free Full Text]
  45. Keyse, S. M. (1995) Biochim. Biophys. Acta 1265, 152-160 [Medline] [Order article via Infotrieve]
  46. Sun, H., Charles, C. H., Lau, L. F., and Tonks, N. K. (1993) Cell 75, 487-493 [Medline] [Order article via Infotrieve]
  47. Jennings, R. B., and Reimer, K. A. (1991) Annu. Rev. Med. 42, 225-246 [CrossRef][Medline] [Order article via Infotrieve]
  48. Ferrari, R., Ceconi, C., Curello, C., Alfieri, O., and Visioli, O. (1994) Eur. Heart J. 14, Suppl. G, 25-30
  49. Webster, K. A., Discher, D. J., and Bishopric, N. H. (1993) J. Biol. Chem. 268, 16852-16858 [Abstract/Free Full Text]
  50. Devary, Y., Gottlieb, R. A., Smeal, T., and Karin, M. (1992) Cell 71, 1081-1091 [Medline] [Order article via Infotrieve]
  51. Cano, E., and Mahadevan, L. C. (1995) Trends Biochem. Sci. 20, 117-122 [CrossRef][Medline] [Order article via Infotrieve]
  52. Minden, A., Lin, A., Smeal, T., Dérijard, B., Cobb, M., Davis, R., and Karin, M. (1994) Mol. Cell. Biol. 14, 6683-6688 [Abstract]
  53. Cano, E., Hazzalin, C. A., and Mahadevan, L. C. (1994) Mol. Cell. Biol. 14, 7352-7362 [Abstract]
  54. Pombo, C. M., Bonventre, J. V., Avruch, J., Woodgett, J. R., Kyriakis, J. M., and Force, T. (1994) J. Biol. Chem. 269, 26546-26551 [Abstract/Free Full Text]
  55. Galcheva-Gargova, Z., Dérijard, B., Wu, I.-H., and Davis, R. J. (1994) Science 265, 806-808 [Medline] [Order article via Infotrieve]
  56. Malarkey, K., Belham, C. M., Paul, A., McLees, A., Scott, P. H., and Plevin, R. (1995) Biochem. J. 309, 361-375 [Medline] [Order article via Infotrieve]
  57. Bogoyevitch, M. A., Clerk, A., and Sugden, P. H. (1995) Biochem. J. 309, 437-443 [Medline] [Order article via Infotrieve]
  58. Rubanyi, G. M., and Polokoff, M. A. (1994) Pharmacol. Rev. 46, 325-415 [Medline] [Order article via Infotrieve]
  59. Hilal-Dandan, R., Urasawa, K., and Brunton, L. L. (1992) J. Biol. Chem. 267, 10620-10624 [Abstract/Free Full Text]
  60. Davis, R. J. (1994) Trends Biochem. Sci. 19, 470-473 [CrossRef][Medline] [Order article via Infotrieve]
  61. Anversa, P., Loud, A. V., Levicky, V., and Guideri, G. (1985) Am. J. Physiol. 248, H876-H882
  62. Anversa, P., Beghi, C., Kikkawa, Y., and Olivetti, G. (1985) Am. J. Pathol. 118, 484-492 [Abstract]
  63. Weber, K. T., Sun, Y., and Guarda, E. (1994) Hypertension 23, 869-877 [Abstract]
  64. Granger, D. N., and Korthuis, R. J. (1995) Annu. Rev. Physiol. 57, 311-332 [CrossRef][Medline] [Order article via Infotrieve]
  65. Pierce, G. N., and Czubryt, M. P. (1995) J. Mol. Cell. Cardiol. 27, 53-63 [Medline] [Order article via Infotrieve]
  66. Pfeffer, J. M., Fischer, T. A., and Pfeffer, M. A. (1995) Annu. Rev. Physiol. 57, 805-826 [CrossRef][Medline] [Order article via Infotrieve]
  67. Huang, Y., and Rane, S. G. (1994) J. Biol. Chem. 269, 31183-31189 [Abstract/Free Full Text]
  68. Sánchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., and Zon, L. I. (1994) Nature 372, 794-798 [Medline] [Order article via Infotrieve]
  69. Dérijard, B., Raingeaud, J., Barrett, T., Wu, I.-H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685 [Medline] [Order article via Infotrieve]
  70. Lin, A., Minden, A., Martinetto, H., Claret, F.-X., Lange-Carter, C., Mercurio, F., Johnson, G. L., and Karin, M. (1995) Science 268, 286-290 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.